May 7, 2014

Medical Device Daily

EndroGastric Solutions gets $30M in private funding for GERD treatment

EndoGastric Solutions (EGS; San Mateo, California), a specialist in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), has raised $30 million in an internal round of financing. 

Existing investors including Advanced Technology Ventures, Canaan Partners, Chicago Growth Partners, De Novo Ventures, Foundation Medical Partners, Oakwood Medical Investors and Radius Ventures participated in the Series G financing round. 


“This is a pivotal time in the company’s evolution,” said Michael Carusi, EGS board member and general partner of Advanced Technology Ventures. “The current management team is focused on a commercialization strategy that is balanced between investments in on-going product development, clinical data, healthcare economics and supporting trained physicians.” 

Full article available via subscription only.